LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models - sprookjes - yvandenbroek - TriplyDB

LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models

LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models

http://www.wikidata.org/entity/Q27675641

about

AXL kinase as a novel target for cancer therapy Structural Mechanisms Determining Inhibition of the Collagen Receptor DDR1 by Selective and Multi-Targeted Type II Kinase Inhibitors Cotargeting MNK and MEK kinases induces the regression of NF1-mutant cancers UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor.Small-molecule inhibitors of the receptor tyrosine kinases: promising tools for targeted cancer therapies An engineered Axl 'decoy receptor' effectively silences the Gas6-Axl signaling axis.Axl as a mediator of cellular growth and survival The promise and challenge of ovarian cancer models.Slow inhibition and conformation selective properties of extracellular signal-regulated kinase 1 and 2 inhibitors Merestinib blocks Mnk kinase activity in acute myeloid leukemia progenitors and exhibits antileukemic effects in vitro and in vivo.Role of met axis in head and neck cancer.Promise and challenges on the horizon of MET-targeted cancer therapeutics Recepteur d'origine nantais (RON), more than a kinase: Role in castrate-resistant prostate cancer.Pharmacophore Mapping Approach for Drug Target Identification: A Chemical Synthesis and in Silico Study on Novel Thiadiazole Compounds.Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma.DDR1 enhances invasion and metastasis of gastric cancer via epithelial-mesenchymal transition.MNK Inhibition Disrupts Mesenchymal Glioma Stem Cells and Prolongs Survival in a Mouse Model of Glioblastoma.Novel investigational therapies for treating biliary tract carcinoma.Approved and Experimental Small-Molecule Oncology Kinase Inhibitor Drugs: A Mid-2016 Overview.MerTK inhibition is a novel therapeutic approach for glioblastoma multiforme.Dramatic antitumor effects of the dual MET/RON small-molecule inhibitor LY2801653 in non-small cell lung cancer.Structural elucidation of the DFG-Asp in and DFG-Asp out states of TAM kinases and insight into the selectivity of their inhibitors.Prognostic Value of Hepatocyte Growth Factor Receptor Expression in Patients with Perihilar Cholangiocarcinoma.Understanding and targeting resistance mechanisms in NSCLC.MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping.Translational control in the tumor microenvironment promotes lung metastasis: Phosphorylation of eIF4E in neutrophils.RON Signaling Is a Key Mediator of Tumor Progression in Many Human Cancers.Immunohistochemical application of a highly sensitive and specific murine monoclonal antibody recognising the extracellular domain of the human hepatocyte growth factor receptor (MET).Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors.Targeting c-MET by LY2801653 for treatment of cholangiocarcinoma.Inhibition of RON kinase potentiates anti-CTLA-4 immunotherapy to shrink breast tumors and prevent metastatic outgrowth

P2860

Q26863442-0AA3F296-DADF-4856-A9C9-C6371EF1234F Q27683558-1CF0A19E-6501-4821-8A4F-D3699C83225E Q28829666-D44B2F72-6EC1-4830-983D-62F9927CCB77 Q34104338-FE5F7869-6943-4FA0-AA33-922458A3E377 Q34158454-A9E47E77-29AB-47D3-8D78-7E3927A03C86 Q34439798-AFEEAA30-32FB-4999-94F6-3889E7F7A5C3 Q34619118-EFB689CB-8A55-4AC5-BF32-4C74C2A4762E Q35771750-B5E327EB-1BB7-4DDC-935D-37F2E83D0BA1 Q36493862-D9D52937-FE37-4555-887C-257A3E0B4CBC Q37117628-9193B0C1-0A6F-4637-9A65-F23F1067B944 Q38167258-AA9FFA09-3358-4DF8-93C2-2D260CA9B597 Q38502350-CDE32301-5B29-4243-B67D-6455B45009D0 Q38543678-5E52E99E-6CDD-4DAE-ABC4-4C3B3B41B380 Q38704262-698B1A02-EFFF-4924-BE07-54FF0E1E8029 Q38718726-AFC4F9F0-2B42-4D46-B41D-CB425EBE7234 Q38737103-DFC4EE1F-94E6-47BB-BBA0-62137F1F2CF9 Q38760569-822E68EF-C6FD-467A-BE73-56AA0C70636A Q38799963-1C0361F0-836F-4B14-A30C-C41A1150D0FC Q38989374-CBF990EA-B248-43B6-9354-453F5D038668 Q39012846-9BA1031D-EB5E-4241-B41D-E1CE777C15CD Q39048792-5366E93A-C44F-4F36-9260-C72C15CB4A3F Q39114170-B7ECCB7E-036B-4F92-AA82-B6296778F158 Q44718464-F51EFDD4-42D5-49DE-B77F-F8FA1F37D364 Q46915997-98120157-A44F-48F6-BC2C-A0A4DB502633 Q47393684-CE6F7FB5-5465-4DA1-B502-5A27DC7229EC Q49790269-926754C3-0DBB-42C3-B7B8-130E54A300E3 Q53591553-15D658EC-85FE-492C-BB72-49900D066A5B Q53878549-2B121DF4-091F-4CF2-9498-8A7EBD7BA375 Q54981810-657E4101-FD21-4844-B5B7-686C212471DE Q55032209-783498C1-5E74-4F11-9DD3-40D7FC6E1BEB Q56891079-409C2347-86AB-48DD-8373-012C12BFB88D

P2860

LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models

http://www.wikidata.org/entity/Q27675641

description

2013 nî lūn-bûn

@nan

2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

LY2801653 is an orally bioavai ...... ties in mouse xenograft models

@ast

LY2801653 is an orally bioavai ...... ties in mouse xenograft models

@en

LY2801653 is an orally bioavai ...... ties in mouse xenograft models

@nl

type

label

LY2801653 is an orally bioavai ...... ties in mouse xenograft models

@ast

LY2801653 is an orally bioavai ...... ties in mouse xenograft models

@en

LY2801653 is an orally bioavai ...... ties in mouse xenograft models

@nl

prefLabel

LY2801653 is an orally bioavai ...... ties in mouse xenograft models

@ast

LY2801653 is an orally bioavai ...... ties in mouse xenograft models

@en

LY2801653 is an orally bioavai ...... ties in mouse xenograft models

@nl

P1433

Q27675641-5D3C8044-F66C-41C7-96C0-126E0D9B9FAA

P1476

Q27675641-CDF2090E-ED85-4E56-8F21-E053DA074C48

P2093

Q27675641-02D4130F-3222-437C-A701-5B401B33872A

Q27675641-098AB393-47A0-45C3-B9F9-B91A017FDECD

Q27675641-16941361-3C7E-4D86-95C7-471EEFC75885

Q27675641-21D10DCE-6316-4B9F-B3D2-2039693A128A

Q27675641-2BE18640-B1B8-4B95-AE6B-5704E0168E36

Q27675641-2E8A95D0-3242-4935-9729-EC874A7C8ECD

Q27675641-4766DBA1-FE8F-4EF2-B79A-290460A1371A

Q27675641-5807B837-2EFA-4C24-883E-C4E5C20D6394

Q27675641-5C0AD149-A481-4479-8D85-304406ACD643

Q27675641-5F633B5C-CFCA-44F8-8C2D-1B9704A860FF

P2860

Q27675641-0187072F-1DB8-4AA8-A042-D965BFE65FD8

Q27675641-156265BF-F2A7-4D3E-9967-D8939B7B6C9F

Q27675641-192E641C-F4E1-4B78-8423-0F3754DF7E69

Q27675641-1E6C93F6-B43D-41A1-9BE8-DAE634F304A1

Q27675641-20A7C651-6F2D-44DB-BE77-2FF4DF1F1F8B

Q27675641-218D76D4-EC76-45D3-9085-62EF2B0DDEB3

Q27675641-272E5EB6-4394-47B8-BFAD-63A3E4104C2A

Q27675641-3B5B133D-AF67-4395-A992-D81E7E64D359

Q27675641-42CE9BEC-CD53-49A2-84C7-DB9B1094E537

Q27675641-4CC8845D-4B05-4CB5-BF95-D8AB6977E6BF

P2888

Q27675641-B36DC9CB-1F18-48EB-A0EE-DDEAB7574D00

P304

Q27675641-B19CD14A-EEEE-40EC-A5E2-412712D8D69C

P31

Q27675641-7FA6D3F1-B4C5-4D06-B4E4-1528A3C09745

P356

Q27675641-C9E647B0-3775-4038-861F-0A610339A549

P433

Q27675641-DD9985F4-51DD-48A3-95B2-DD629D10DF5F

P478

Q27675641-94318801-5E40-46BF-8DD2-452F3FB554F9

P577

Q27675641-D0AC51E3-D90B-434E-96EC-43F35FF0C1E2

P5875

Q27675641-9A233C25-EC70-45C1-867A-99888B45D6E3

P6179

Q27675641-36693219-6C7C-46AC-B5AD-F932005C947C

P698

Q27675641-548E4151-C721-4214-A81F-1A61BA72F2D7

P921

Q27675641-79EA9269-E7AA-4B04-AFFA-CFD28024DFB2

P932

Q27675641-3A5CDFF1-4F50-47CB-803E-BF2BA87789F8

P356

S10637-012-9912-9

P1433

Investigational New Drugs

P1476

LY2801653 is an orally bioavai ...... ties in mouse xenograft models

@en

P2093

Boyu Zhong

http://www.w3.org/2001/XMLSchema#string

Bruce W Konicek

http://www.w3.org/2001/XMLSchema#string

Chuan Shih

http://www.w3.org/2001/XMLSchema#string

Jason R Manro

http://www.w3.org/2001/XMLSchema#string

Jeremy R Graff

http://www.w3.org/2001/XMLSchema#string

Julie A Stewart

http://www.w3.org/2001/XMLSchema#string

Karen L Huss

http://www.w3.org/2001/XMLSchema#string

Lei Yan

http://www.w3.org/2001/XMLSchema#string

Mark T Uhlik

http://www.w3.org/2001/XMLSchema#string

Richard A Walgren

http://www.w3.org/2001/XMLSchema#string

P2860

Structural characterization of autoinhibited c-Met kinase produced by coexpression in bacteria with phosphatase.

Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

ROS1 rearrangements define a unique molecular class of lung cancers.

Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.

Coot: model-building tools for molecular graphics

Refinement of macromolecular structures by the maximum-likelihood method

Met, metastasis, motility and more

P2888

s10637-012-9912-9

P304

833-44

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10637-012-9912-9

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P577

2013-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

234011704

http://www.w3.org/2001/XMLSchema#string

P6179

1049998574

http://www.w3.org/2001/XMLSchema#string

P698

23275061

http://www.w3.org/2001/XMLSchema#string

P921

P932

3717159

http://www.w3.org/2001/XMLSchema#string